The prognostic significance of PD-L1 in bladder cancer

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 3075-3084

  Huang, Yide ^a   Zhang, Shu Dong ^b   McCrudden, Cian ^b   Chan, Kwok Wah ^c   Lin, Yao ^a,d   Kwok, Hang Fai ^b,d  

^a FUJIAN NORMAL UNIVERSITY   (China)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d University of Macau   (Macao)

Author keywords

Bladder cancer; Patient survival; Prognostic marker; Programmed death ligand 1; Therapeutic targets

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; PROGRAMMED DEATH 1 LIGAND 1; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ATEZOLIZUMAB; CD274 PROTEIN, HUMAN; INDUCIBLE T CELL COSTIMULATOR LIGAND; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MOTIF; TUMOR ASSOCIATED LEUKOCYTE; AGED; BIOSYNTHESIS; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INDUCIBLE T-CELL CO-STIMULATOR LIGAND; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; URINARY BLADDER NEOPLASMS;

EID: 84928898064     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3933     Document Type: Article

References (25)

1. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ and Sharma P: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7: 10, 2007.
2. Redelman-Sidi G, Glickman MS and Bochner BH: The mechanism of action of BCG therapy for bladder cancer - a current perspective. Nat Rev Urol 11: 153-162, 2014.
3. Alexandroff AB, Jackson AM, O'Donnell MA and James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694, 1999.
4. Chen DS, Irving BA and Hodi FS: Molecular pathways: Next-generation immunotherapy - inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18: 6580-6587, 2012.
5. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K and Ueda S: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182, 2007.
6. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L and Kwon ED: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 109: 1499-1505, 2007.
7. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED and Frank I: T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival. Clin Cancer Res 14: 4800-4808, 2008.
8. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, et al: Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 40: 121-127, 2014.
9. Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Zambrano CC, Bellmunt J, Burris HA, Teng SM, et al: Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol (ASCO Meeting Abstracts) 32: 5011, 2014.
10. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ and Chu IS: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 28: 2660-2667, 2010.
11. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al: A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18: 3377-3386, 2012.
12. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson W, et al: Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 7: e38863, 2012.
13. Kulbe H, Levinson NR, Balkwill F and Wilson JL: The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol 48: 489-496, 2004.
14. Corthay A: Does the immune system naturally protect against cancer? Front Immunol 5: 197, 2014.
15. Kyi C and Postow MA: Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588: 368-376, 2014.
16. Langer CJ: Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): The role of immune checkpoint inhibitors. Am J Clin Oncol: Mar 28, 2014 (Epub ahead of print).
17. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM and Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130: 1109-1119, 2012.
18. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ and Goodison S: CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 7: e37797, 2012.
19. Goodison S, Chang M, Dai Y, Urquidi V and Rosser CJ: A multianalyte assay for the non-invasive detection of bladder cancer. PLoS One 7: e47469, 2012.
20. Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S and Rosser CJ: Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urol 13: 42, 2013.
21. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
22. Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity 39: 1-10, 2013.
23. Gandhi C, Khan MM, Lentz SR and Chauhan AK: ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 119: 2385-2391, 2012.
24. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F and Wagner DD: ADAMTS13: A new link between thrombosis and inflammation. J Exp Med 205: 2065-2074, 2008.
25. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang JJ, Kamimura D, et al: Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74: 8-14, 2014.